← Back to Search

Behavioural Intervention

Diabetes BOOST Program for Type 2 Diabetes

N/A

Waitlist Available

Led By Daniel J Amante, PhD, MPH

Research Sponsored by Daniel Amante

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age > 18 years

Diagnosis of type 2 diabetes

Must not have

Cognitive impairment

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 - 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to develop a culturally-appropriate diabetes self-management program for Latinx patients, tested in collaboration with clinical, community and patient partners.

Who is the study for?

This trial is for Hispanic/Latinx adults over 18 with type 2 diabetes who prefer to speak Spanish and have completed a diabetes self-management training in the past year. It's not suitable for those with cognitive impairments, pregnant women, or current prisoners.

What is being tested?

The study is testing 'DM-BOOST para Latinx,' an adapted version of the DM-BOOST program designed to help Latinx patients manage their diabetes using behavioral economics and technology. The effectiveness will be assessed through community-based participatory research.

What are the potential side effects?

Since this intervention involves educational and support programs rather than medications, traditional side effects are not expected. However, participants may experience stress or discomfort related to lifestyle changes encouraged by the program.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am older than 18 years.

Select...

I have been diagnosed with type 2 diabetes.

Select...

I completed a diabetes self-management training last year.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have difficulty with memory or thinking clearly.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 - 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 - 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 - 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Process Evaluation

Secondary study objectives

Change in HbA1c Percentage

Diabetes self-efficacy

Diabetes treatment satisfaction

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention - Diabetes BOOSTExperimental Treatment1 Intervention

Intervention group participants will complete a baseline survey, receive a referral to DSMT from the research team, a mailed welcome letter and self-care education sent via a series of personalized patient portal secure messages, text messages, and video call. They will be sent text messages with information about one of the American Association of Diabetes Educators 7 self-care behaviors and will receive encouragement to author their own self-management behavioral goals. Participants will also complete a telehealth training video call with research staff to review the functionality of their patient portal and refine diabetes-related goals. The participant will then be encouraged to send a patient portal message to their DSMT CDCES that includes their personalized goals prior to their scheduled DSMT session. They will then complete a 3-month follow-up survey and qualitative interview.

Group II: Usual CareActive Control1 Intervention

Comparison Group participants will complete a baseline survey, receive a DSMT referral request from research team to their primary care provider and a mailed welcome letter. The mailed letter will welcome the participant to the study and contain general information about diabetes self-care behaviors and goal setting. They will complete a DSMT session. They will then complete a 3-month follow-up survey and qualitative interview.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Diabetes BOOST

2021

N/A

~70

0 / 4Eligibility criteria met